Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Temozolomide (TMZ), an alkylating agent, is widely used for treating primary and recurrent
high-grade gliomas. However, the efficacy of TMZ is often limited by the development of …

Background Malignant glioma is the most common and lethal primary brain tumour, with
dismal survival rates and no effective treatment. We examined the safety and activity of NSC …

The role of autophagy in cancer onset and progression appears still controversial. On one
hand, autophagy allows cancer cell to survive in unfavorable environmental conditions, on …

Purpose: Telomerase activity is one of the hallmarks of cancer and is a highly relevant
therapeutic target. The effects of a novel human telomerase antagonist, imetelstat, on …

Oncolytic adenoviruses and certain chemotherapeutics can induce autophagy and
immunogenic cancer cell death. We hypothesized that the combination of oncolytic …

Oncolytic adenoviruses, such as Delta-24-RGD, are promising therapies for patients with
brain tumor. Clinical trials have shown that the potency of these cancer-selective …

Adenoviral vectors (AdVs) have attracted much attention in the fields of vaccine
development and treatment for diseases such as genetic disorders and cancer. In this …

The ICP34. 5 protein of herpes simplex virus (HSV) is involved in many aspects of viral
pathogenesis; promoting neurovirulence, inhibiting interferon-induced shutoff of protein …

The long-term efficacy of targeted therapeutics for cancer treatment can be significantly
limited by the type of therapy and development of drug resistance, inter alia. Experimental …